EBMT 2022: Updated results of a study investigating CAR T therapy Axicabtagene ciloleucel as second line treatment for relapsed large cell lymphomas.
Home / Resource Library / Axi-Cel Shows Clinically Meaningful Improvement in QOL in Second Line Relapsed/Refractory LBCL